The Russian Direct Investment Fund (RDIF) and Panacea Biotec have announced the supply of the first shipment out of one million doses of the second component (human adenovirus serotype 5) of the Russian Sputnik V coronavirus vaccine manufactured by Panacea Biotec for sale in India, the company said in a statement.
This is the first batch of the second component produced and supplied by the company in India. Doses of the second component of Sputnik V have been manufactured at the Panacea Biotec’s state-of-the-art vaccine manufacturing facility in Himachal Pradesh. The company received necessary clearance from the Central Drug Laboratories (CDL), Kasauli on 31st August, 2021, the statement mentioned.
It also notified that the full-scale production of Spuntik V started at Panacea Biotec’s facilities this summer. Facilities comply with GMP standards and are prequalified by the World Health Organization (WHO).
According to the statement, the batch will be distributed in India through a partner of RDIF and Panacea Biotec-Dr Reddy’s Laboratories.
Speaking in this regard, Dr Rajesh Jain, Managing Director, Panacea Biotec, said, “Panacea Biotec is pleased to have successfully produced and dispatched the first batch of Component II (Ad5) of Sputnik V vaccine. More batches are currently under production at our manufacturing facility in Himachal Pradesh.”